BioSyntech, Inc., a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Mr. Louis Lemire, CA, to the to the position of Chief Financial Officer. Mr. Lemire joined the Company as a consultant in October 2008 and was appointed Vice President, Finance in December 2008.
“Louis has become well versed in the financial aspects of BioSyntech and has been a strong addition to our team,” said Michel Lagueux, Chairman of the Board of Directors. “We are pleased that he will take a broader role in the operations and strategic development of our Company as we advance our lead product for cartilage repair, BST-CarGel®, towards commercialization.”
Mr. Lemire is a chartered accountant with more than 20 years of experience in finance and accounting, mainly in the biotechnology, high tech and telecommunication industries. Prior to joining BioSyntech, he was a consultant for GlaxoSmithKline Biologicals North America; he was also Vice President, Finance for MediSolution Ltd during the restructuring of this company and held other management positions in companies such as AT&T Canada, Metronet Communications, Posicom and NHC Communications.